SLU-PP-332: Research Profile and Protocol Guide

Overview

SLU-PP-332 is a small molecule agonist of estrogen-related receptors alpha and gamma (ERRa/ERRy), developed at Saint Louis University. While technically not a peptide, it is commonly offered by research peptide suppliers due to its metabolic research applications. SLU-PP-332 has gained significant attention as an 'exercise mimetic' - a compound that activates many of the same molecular pathways triggered by physical exercise, including mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber development. In preclinical studies published in 2023-2024, SLU-PP-332 treatment increased the proportion of fatigue-resistant oxidative muscle fibers, enhanced endurance capacity, and reduced body weight in mice, all without increased physical activity. The compound represents an emerging area of research into pharmacological exercise mimetics and metabolic optimization. Research is very early-stage with limited published data.

Mechanism of Action

SLU-PP-332 activates ERRa and ERRy, nuclear receptors that serve as master regulators of mitochondrial biogenesis and oxidative metabolism. These receptors control the expression of genes involved in oxidative phosphorylation, fatty acid oxidation, the TCA cycle, and mitochondrial DNA transcription. When activated by SLU-PP-332, ERR receptors upregulate PGC-1alpha-dependent gene programs that convert glycolytic (fast-twitch) muscle fibers into oxidative (slow-twitch, fatigue-resistant) fibers. This fiber-type switching increases mitochondrial density and oxidative capacity in skeletal muscle. The compound also activates lipid metabolism pathways, reducing adipose tissue accumulation and improving metabolic markers in animal models.

Research Applications

Exercise mimetic research, mitochondrial biogenesis, muscle fiber type research, metabolic optimization, obesity and body composition studies, endurance and fatigue research, ERR receptor pharmacology

Research Protocols

Safety Profile and Considerations

Very limited safety data. Only preclinical studies published. No human trials. Potential concerns around cardiac effects (ERR receptors are expressed in heart tissue). Long-term effects unknown. Not FDA approved. Extremely early-stage research compound.

Storage and Stability

Room temperature, protect from moisture and light. See our storage and handling guide for comprehensive best practices.

Published Research

• Rangwala SM, et al. Estrogen-related receptors in metabolic regulation. Trends Pharmacol Sci. 2012
  PMID: 22503442
• Narkar VA, et al. Exercise-like effects in sedentary mice. Cell. 2008
  PMID: 18674809

Search for additional SLU-PP-332 research on PubMed.

Where to Source SLU-PP-332

Peptide purity is critical for research accuracy. We evaluate suppliers against our 100-point methodology.